AUTHORS
Bret Jensen
Recent Articles By The Author
On Dreams of Yesteryear and Covered Calls
The ability to execute options plays at cheap prices is a big change from a quarter-century ago, and small investors would do well to employ them.
PulteGroup Is in a Prime Position as New Housing Demand Grows
This is one of few homebuilder equities that did not have a big move up in 2020 and the stock is cheap.
Fingers Crossed for a Couple $2 Lottery Tickets in My Portfolio
T2 Biosystems and Tyme Technologies have both perked up of late after languishing for extended periods of time.
2 Small-Caps Still Worth Considering in This Red-Hot Market
Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.
Here's My Biotech Pick for 2021
But know first that to really succeed in the sector, diversifying is key.
The Market Will Pay for Its Complacency
Participants largely have ignored the risks to stocks posed by the makeup of the government and the lingering coronavirus, and that could be costly.
This Long-Only Investor Feels Stuck as 2021 Begins
It's hard to find value in a picked-over market trading at all-time highs, which leaves this participant building his cash position.
Looking to Exploit a Few Pandemic Trends That Will Continue in 2021
The virtual work force, online shopping and a love of pets are not going to go away even after the coronavirus abates.
3 Predictions for 2021 and How They'll Impact Stocks
Look for a weaker dollar to perk up the energy sector, the exodus from big cities to continue, and gun and ammo sales to remain strong
Here Are 2 'Stocking Stuffers' for Covered Call Aficionados
I added to my stake in UniQure and initiated a new position in Lexicon Pharmaceuticals.
Oops!
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Please Join or Log In to Email Our Authors.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login